John J. Kirby
CIK 1556327 · Interim CFO · last filed 2026-08-18
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
VRCA price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
505 EAGLEVIEW BLVD., SUITE 212
EXTON, PA 19341
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| VRCA | Interim CFO | 23,962 | $3.59 | $86.0K | $39.7K | 4 | 2026-08-18 |
| Aceragen, Inc. (ACGN) Delisted | CHIEF FINANCIAL OFFICER | — | $0.38 | — | $0 | 1 | 2023-02-02 |
| Aceragen, Inc. (IDRA) Delisted | CHIEF FINANCIAL OFFICER | 25,697 | $7.22 | $185.7K | -$16.5K | 15 | 2023-01-10 |
| VIROPHARMA INC (VPHM) Delisted | V.P., Chief Accounting Officer | — | — | — | $0 | 3 | 2013-06-12 |
Recent Filings · Page 2 of 3
25 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2021-12-21 | Aceragen, Inc. (IDRA) Delisted | Buy (P) | +10,000 | $6.2K | EDGAR |
| 2021-07-12 | Aceragen, Inc. (IDRA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-03-29 | Aceragen, Inc. (IDRA) Delisted | Sell (S) | −6,250 | -$8.9K | EDGAR |
| 2021-01-12 | Aceragen, Inc. (IDRA) Delisted | Mixed | −1,693 | -$7.2K | EDGAR |
| 2021-01-06 | Aceragen, Inc. (IDRA) Delisted | Sell (S) | −862 | -$3.4K | EDGAR |
| 2020-07-23 | Aceragen, Inc. (IDRA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-01-14 | Aceragen, Inc. (IDRA) Delisted | Grant (A) | +20,000 | $0 | EDGAR |
| 2020-01-14 | Aceragen, Inc. (IDRA) Delisted | Sell (S) | −911 | -$1.6K | EDGAR |
| 2020-01-10 | Aceragen, Inc. (IDRA) Delisted | Sell (S) | −911 | -$1.6K | EDGAR |
| 2019-07-11 | Aceragen, Inc. (IDRA) Delisted | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.